Presentation is loading. Please wait.

Presentation is loading. Please wait.

Joshua Plants, RN, BSN. At the completion of this presentation you should be able to: Define Hypodermoclysis State the indications and contraindications.

Similar presentations

Presentation on theme: "Joshua Plants, RN, BSN. At the completion of this presentation you should be able to: Define Hypodermoclysis State the indications and contraindications."— Presentation transcript:

1 Joshua Plants, RN, BSN

2 At the completion of this presentation you should be able to: Define Hypodermoclysis State the indications and contraindications for this therapy Identify acceptable infusion sites

3 Relate the types of solutions used State the potential complications of therapy Understand monitoring parameters and documentation responsibilities

4 Contributing factors to dehydration Kidney Reduction in size and nephron function Decreased GFRdecreased ability to concentrate urine, balance H20, K and Na Homonal changes ADH, ANP, Aldosterone Regulate fluids and electrolytes

5 Contributing factors to dehydration Body fluid content Young adult 60%--older adult 40% Decreased sensation of thirst (Scales, 2011)

6 Increased morbidity and mortality Mental function Increased irritation, behaviors, cognition problems, confusion Infection Renal stones Falls Constipation Thrombosis (Scales, 2011)

7 Compounding factors: Fears of incontinence Inability to obtain drinks/liquids Lack of access to fluids of choice Temperature (Remington & Hultman, 2007)


9 Treatment /Prevention of mild to moderate dehydration Clysis for short Administration of fluids to the hypodermis Subcutaneous infusion Between skin and fascia



12 SUBCUTANEOUS Easy to initiate and maintain Minimal complications Edema Insertion site issues Inadvertent IV access Can be difficult for staff to initiate or maintain Missed doses Precise locations Therapeutic levels Multitude of potential complications Phlebitis Infiltration Sepsis Fluid Overload Catheter related issues INTRAVENOUS

13 Go to Maine State Board of Nursing Website At the far right select the hyperlink entitled Practice Questions Select the link entitled Scope of Practice Decision Tree Use tree to determine SOP

14 Ease of access with subcutaneous administration Easy for nurses to insert and maintain Minimal number of complications when compared to intravenous therapy Minor complications with SC versus IV

15 Reduced levels of patient discomfort Size of needles Number of rotations required Care provider technique Reduces potential for hospitalization $1 billion annual US cost of avoidable hospitalizations for dehydration (Lybarger, 2009) Re-hospitalization Nosocomial infection

16 Cost effective Subcutaneous fluid group cost much lower than IV group (Sasson and Shvartzman, 2001) Per kit price $13.74; case of five $68.70 Nursing time costs; education Admission/Re-admission

17 Limited volume of administration Localized edema is created Isotonic or near isotonic fluids only No medications Gravity versus pump Sub-Q versus IV Reimbursement rates

18 Mild to moderate dehydration Adults, Children, Geriatrics Alternative to the intravenous route When intravenous access cannot be achieved or reliably maintained

19 Emergency situations Shock Circulatory failure Severe dehydration Severe electrolyte imbalance Coagulopathy/blood dyscrasia Fluid overload Congestive heart failure Marked edema Ascites

20 Need for additional intravenous medications or antibiotics Renal dialysis Need for precise control of fluid balance Lack of sufficient subcutaneous tissue to safely perform the therapy (cachectic)

21 The preferred solution is 0.9% sodium chloride (normal saline) Other solutions include: Lactated ringers (LR) D5 ½ NS D5 NS D5 LR D5 ¼ NS D2.5 in ½ NS

22 D5W and D10W solutions are not recommended as the dextrose component is quickly metabolized. The remaining free water is hypotonic and causes a subsequent osmotic draw in the reverse direction of that which is desired. Increased edema and secondary discomfort is likely to result. Glucose pH 3.5-6.5 (acidic); no greater than 5% Osmolality less than 280 mOs/kg (Medicines Information, 2001)

23 Note: No medications should be added to subcutaneous hydration solutions. Exception: hyaluronidaseHydase, Amphadase, Wydase Used to enhance fluid absorption by decreasing viscosity of subcutaneous tissue Dose: 150 units (Clinical Pharmacology, 2013) NOTE: SUB-q bolus, DO NOT add to solution bag

24 Rates of infusion are based on gauge size and device type. Manufacturers recommendations should be followed. Norfolk Medical MarCal Medical Churchhill Medical Systems Smiths Medical pages/promotions/md/cleo-home.html pages/promotions/md/cleo-home.html

25 Lumens Single80 ml/hour Double62 ml/hour at each of two sites Total Rate: 124 ml/hour Multipleused for non-hydration sub-q therapies

26 Sizes 6-20 mm lengths Shortest possible size based on subcutaneous tissue Cleo6mm Marcal6mm Aqua-C9mm 21-29 gauge Cleo29 ga Marcal27 ga Aqua-C25 ga

27 Abdomen Note: area within two inch radius of umbilicus excluded Anterior or lateral thigh Note: avoid in ambulatory patients Posterior upper arms Anterior chest wall Subscapular Lower back

28 AVOID: Scarred tissue, bruised areas, areas of impaired skin integrity Areas prone to mechanical friction from clothes, equipment or patient movement Edematous areas Painful or infected areas Hard or bony areas, near the breast(s), perineum or waistline Dependent areas Poorly vascularized

29 After: 1500-2000 ml/24 hours at single site 3000 ml/24 hours for double site Q24-48 hours New site proximity When complications are noted PRN Positional

30 Site surveillance/monitoring should occur a minimum of every two hours: Erythema Gross swelling/edema Leakage Pain/discomfort Overall patient tolerance of therapy

31 Risks are minimal when indications, guidelines and P&P are followed. Adverse effects are rare and related to: Solution type Volume administered Rate of infusion

32 Edema Most common Massage Redness, swelling and inflammation at infusion site 5% of 46 patients with clysis versus 25% of 18 patients IV (Sasson and Shvartzman, 2001)

33 Cellulitis Technique Rotation Pain/discomfort Technique Rate Infection Oversaturation

34 Inadvertent IV access Check for blood return (INS, 2011) Pulmonary edema 0.6% of 600+ patients (Sasson and Shvartzman, 2001)

35 Problem Patient requires short term hydration for mild to moderate dehydration. Potential for leakage, prominent swelling and localized infection

36 Goal/Outcome Patient will return to baseline hydration level Patient will not develop erythema, prominent swelling, pain, drainage or elevated temperature for duration of therapy Access will remain patent

37 Interventions Ensure clean/aseptic technique is maintained for all clysis procedures Including during needle rotation Administer the correct solutions for the type of therapy Select appropriate sites for subcutaneous infusion Avoid aforementioned site selection locations

38 Interventions Monitor site Q2 hours during therapy At least once per shift Change dressings PRN Ensure ordered rates are maintained 80 ml/hour at single site 62 ml/hour at double site (total 124 ml/hour)

39 Interventions Rotate needle sites Q 24-48 hours during therapy After 1.5-2 liters at single site After 3 liters at double site PRN Provide staff with safety needle technology Needle-stick prevention Non-metal devices preferred (INS, 2011) Needle-stick Increased dwell

40 Interventions Use administration sets with rate flow controller or electronic infusion device (INS, 2011) CAUTION: Pumping fluids into subcutaneous tissue may mask oversaturation Increased edema and pain/discomfort Notify physician/LIP with complications

41 Follow local/institutional policy and procedures Valid prescriber order for therapy Use MAR/TAR/POS specific to therapy as indicated

42 Specific data to be documented by the nurse in the medical record include: Date and time Medications/solutions to be infused Rate of infusion and start/stop times Device specific information

43 Site selection/assessment Complications noted during therapy Interventions and inter-disciplinary communication Patient/family teaching Patient response to therapy

44 Medicines Information Centre at Calderdale Royal Hospital. (2001). Hypodermoclysis-subcutaneous administration of fluids. Pharmacy news, 7(4). Omnicare. (2012). Hypodermoclysis. Sasson, M., & Shvartzman, P. (2oo1). Hypodermoclysis: An alternative infusion technique. American Family Physician, 64(9), 1575-1578. Infusion Nurses Society. (2011). Infusion nursing standards of practice. Journal of Infusion Nursing, 34(1S), S84-85.

45 Lybarger, E. (2009) Hypodermoclysis in the home and long-term care settings. Journal of Infusion Nursing, 32(1), p.40-44. Clinical Pharmacology. (2013). Wydase. Retrieved from: Scales, K. (2011). Use of hypodermoclysis to manage dehydration. Nursing Older People, 23(5), 16-22. Remington, R., & Hultman, T. (2007). Hypodermoclysis to treat dehydration: a review of the evidence. Journal Of The American Geriatrics Society, 55(12), 2051-2055.

Download ppt "Joshua Plants, RN, BSN. At the completion of this presentation you should be able to: Define Hypodermoclysis State the indications and contraindications."

Similar presentations

Ads by Google